LLY

1,021.31

-0.16%↓

JNJ

210.71

+0.31%↑

ABBV

221.72

-1.34%↓

UNH

342.2

+2.84%↑

AZN

89.62

-1.82%↓

LLY

1,021.31

-0.16%↓

JNJ

210.71

+0.31%↑

ABBV

221.72

-1.34%↓

UNH

342.2

+2.84%↑

AZN

89.62

-1.82%↓

LLY

1,021.31

-0.16%↓

JNJ

210.71

+0.31%↑

ABBV

221.72

-1.34%↓

UNH

342.2

+2.84%↑

AZN

89.62

-1.82%↓

LLY

1,021.31

-0.16%↓

JNJ

210.71

+0.31%↑

ABBV

221.72

-1.34%↓

UNH

342.2

+2.84%↑

AZN

89.62

-1.82%↓

LLY

1,021.31

-0.16%↓

JNJ

210.71

+0.31%↑

ABBV

221.72

-1.34%↓

UNH

342.2

+2.84%↑

AZN

89.62

-1.82%↓

Начало・Списък с акции・Vaxart Inc

Vaxart Inc

Затворен

0.32

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

0.32

Максимум

0.32

Ключови измерители
By Trading Economics
Приходи	6.8M -8.1M
Продажби	33M 72M
EPS	-0.04
Марж на печалбата	-11.242
Служители	105
EBITDA	6.7M -5.4M

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-2.5M 89M
Предишно отваряне	0.32
Предишно затваряне	0.32

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

0.4007 / 0.4252 Подкрепа & съпротива

Vaxart Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

11.12.2025 г., 23:58 ч. UTC

Придобивния, сливания и поглъщания

Destination XL to Merge With Oaktree-Backed Fullbeauty Brands -- Update

11.12.2025 г., 23:56 ч. UTC

Печалби

Costco Logs Higher Sales, Eyes Expansion to Fuel Membership Growth -- Update

11.12.2025 г., 23:03 ч. UTC

Придобивния, сливания и поглъщания

FTC Sues to Block Henkel's $725 Million Acquisition of Liquid Nails From PE Firm

11.12.2025 г., 22:06 ч. UTC

Придобивния, сливания и поглъщания

Scentre to Sell $456 Million Westfield Chermside Mall Stake to Dexus-Managed Fund

11.12.2025 г., 21:50 ч. UTC

Печалби

Costco Same-Store Sales, Membership Fees Rose in 1Q

11.12.2025 г., 23:45 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

11.12.2025 г., 23:44 ч. UTC

Пазарно говорене

Nikkei May Rise After U.S. Stock Indexes Hit Record Highs -- Market Talk

11.12.2025 г., 23:37 ч. UTC

Пазарно говорене

Gold Steady, Underpinned by Dollar's Weakness -- Market Talk

11.12.2025 г., 23:31 ч. UTC

Печалби

Broadcom Beats Revenue and Profit Forecasts as AI Chip Sales Climb -- Update

11.12.2025 г., 22:48 ч. UTC

Придобивния, сливания и поглъщания

FTC Sues to Block Henkel's $725M Acquisition of Liquid Nails From PE Firm

11.12.2025 г., 22:35 ч. UTC

Печалби

Costco Sold 4.5 Million Pies Ahead of Thanksgiving. Despite Earnings Beat, the Stock Fails to Gain Traction. -- Barrons.com

11.12.2025 г., 22:30 ч. UTC

Печалби

Broadcom Beats Earnings. The Stock Wavers After Customer Updates. -- Barrons.com

11.12.2025 г., 22:09 ч. UTC

Придобивния, сливания и поглъщания

FTC Alleges Henkel Deal Would Combine Two Biggest Brands of Construction Adhesives Sold at Stores Like Home Depot, Leading to Higher Prices

11.12.2025 г., 22:06 ч. UTC

Придобивния, сливания и поглъщания

FTC Sues to Block Henkel From Buying Loctite Competitor Liquid Nails

11.12.2025 г., 22:05 ч. UTC

Печалби

Broadcom Beats Revenue and Profit Forecasts as AI Chip Sales Climb -- Update

11.12.2025 г., 21:51 ч. UTC

Придобивния, сливания и поглъщания

Scentre to Sell $456M Westfield Chermside Mall Stake to Dexus-Managed Fund

11.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

11.12.2025 г., 21:39 ч. UTC

Печалби

Broadcom Beats Earnings. The Stock Rises. -- Barrons.com

11.12.2025 г., 21:39 ч. UTC

Печалби

Broadcom Reports $18 Billion in Revenue as AI Chip Sales Climb -- WSJ

11.12.2025 г., 21:38 ч. UTC

Печалби

Costco Tops Earnings Estimates but Stock Fails to Gain Traction -- Barrons.com

11.12.2025 г., 21:37 ч. UTC

Печалби

These Stocks Moved the Most Today: Oracle, Nvidia, Broadcom, Planet Labs, Visa, Ciena, Gemini Space Station, and More -- Barrons.com

11.12.2025 г., 21:37 ч. UTC

Пазарно говорене

Broadcom Sees AI Revenue Doubling -- Market Talk

11.12.2025 г., 21:34 ч. UTC

Придобивния, сливания и поглъщания

Scentre Will Temporarily Invest A$50M in the New Dexus Fund

11.12.2025 г., 21:29 ч. UTC

Придобивния, сливания и поглъщания

Dexus Aiming for Long-Term Holding of A$50M in Fund

11.12.2025 г., 21:28 ч. UTC

Пазарно говорене

BLS Publishing Calendar Delays Now Pushing Economic Data Into February -- Market Talk

11.12.2025 г., 21:28 ч. UTC

Придобивния, сливания и поглъщания

Dexus Expects to Introduce Additional Third-Party Equity in FY26

11.12.2025 г., 21:28 ч. UTC

Придобивния, сливания и поглъщания

Dexus: Third Party Investors to Contribute Remainder

11.12.2025 г., 21:27 ч. UTC

Придобивния, сливания и поглъщания

Dexus to Put Initial A$170M into New Dexus Strategic Investment Trust

11.12.2025 г., 21:26 ч. UTC

Придобивния, сливания и поглъщания

Scentre: Dexus Wholesale Shopping Centre Fund Already Holds 25% Stake

11.12.2025 г., 21:25 ч. UTC

Придобивния, сливания и поглъщания

Scentre: Purchase Price Represents Book Value, 5% Value Cap Rate

Сравнение с други в отрасъла

Ценова промяна

Vaxart Inc Прогноза

Консенсусна оценка

By TipRanks

0 ratings

Купи

Задържане

Продай

Според 0 анализатори, дали борсови рейтинги на Vaxart Inc през последните 3 месеца.

Техническа оценка

By Trading Central

0.4007 / 0.4252Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bearish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.